Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine effects on NETosis and angiogenesis biomarkers in postoperative breast cancer under different anesthesia methods
ChiCTR2300068563Phase 4Not yet recruiting
- Sponsor
- General Hospital of Ningxia Medical University
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of lidocaine in breast cancer (4 arms), sponsored by General Hospital of Ningxia Medical University. Primary endpoints: neutrophil myeloperoxidase, citrullinated histone H3 and 3 more. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
lidocaine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2300068563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068563.